Why High-Concentration Biologics Demand a New Approach to Formulation Science

The biopharmaceutical landscape is undergoing a structural shift toward greater molecular complexity and formulation concentrations exceeding 100 mg/mL. High-concentration formulations, particularly those intended for subcutaneous administration, present a distinct set of technical challenges that conventional development approaches were not designed to address. Samsung Biologics’ proprietary S-HiCon™ platform provides an integrated, data-driven framework for navigating these challenges, encompassing early material generation, structured excipient screening, and advanced analytical characterization.